MCID: RTN018
MIFTS: 53

Retinal Disease

Categories: Eye diseases, Neuronal diseases, Rare diseases

Aliases & Classifications for Retinal Disease

MalaCards integrated aliases for Retinal Disease:

Name: Retinal Disease 12 15 39
Retinal Diseases 44 15 70
Retinal Disorders 42

Classifications:



External Ids:

Disease Ontology 12 DOID:5679
ICD9CM 34 362.9
MeSH 44 D012164
NCIt 50 C26875
SNOMED-CT 67 29555009
ICD10 32 H35.8 H35.9 H36
UMLS 70 C0035309

Summaries for Retinal Disease

MedlinePlus : 42 The retina is a layer of tissue in the back of your eye that senses light and sends images to your brain. In the center of this nerve tissue is the macula. It provides the sharp, central vision needed for reading, driving and seeing fine detail. Retinal disorders affect this vital tissue. They can affect your vision, and some can be serious enough to cause blindness. Examples are Macular degeneration - a disease that destroys your sharp, central vision Diabetic eye disease Retinal detachment - a medical emergency, when the retina is pulled away from the back of the eye Retinoblastoma - cancer of the retina. It is most common in young children. Macular pucker - scar tissue on the macula Macular hole - a small break in the macula that usually happens to people over 60 Floaters - cobwebs or specks in your field of vision NIH: National Eye Institute

MalaCards based summary : Retinal Disease, also known as retinal diseases, is related to aland island eye disease and usher syndrome, type iia, and has symptoms including eye manifestations An important gene associated with Retinal Disease is GUCY2D (Guanylate Cyclase 2D, Retinal), and among its related pathways/superpathways are Phototransduction and Metabolism of fat-soluble vitamins. The drugs Levoleucovorin and Pioglitazone have been mentioned in the context of this disorder. Affiliated tissues include retina, eye and endothelial, and related phenotypes are nervous system and cardiovascular system

Disease Ontology : 12 An eye disease that is located in the retina.

Wikipedia : 73 The retina (from Latin: rete) is the innermost, light-sensitive layer of tissue of the eye of most... more...

Related Diseases for Retinal Disease

Diseases in the Retinal Disease family:

Inherited Retinal Disorder Rare Retinal Disorder

Diseases related to Retinal Disease via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 496)
# Related Disease Score Top Affiliating Genes
1 aland island eye disease 32.3 RPE65 NR2E3 GUCY2D CACNA1F ABCA4
2 usher syndrome, type iia 32.3 USH2A CEP290 ABCA4
3 retinal degeneration 32.2 USH2A RPGR RPE65 RLBP1 RHO PRPH2
4 night blindness 32.2 USH2A RPGR RPE65 RLBP1 RHO PRPH2
5 leber plus disease 32.2 USH2A RPGR RPE65 RLBP1 RHO PRPH2
6 vitreoretinochoroidopathy 32.1 RPE65 PRPH2 PRPF31 BEST1 ABCA4
7 enhanced s-cone syndrome 32.1 RPGR RPE65 RHO NR2E3 CRX
8 choroidal dystrophy, central areolar, 1 32.1 RPE65 PRPH2 NR2E3 GUCY2D GUCA1A CRX
9 stargardt disease 32.1 USH2A RPGR RPE65 RLBP1 RHO PRPH2
10 cone dystrophy 32.1 USH2A RPGR RPE65 RLBP1 RHO PRPH2
11 prolonged electroretinal response suppression 32.0 RHO NR2E3 GUCA1A
12 cone dystrophy 3 31.9 RHO GUCA1A
13 retinitis 31.8 USH2A RPGR RPE65 RLBP1 RHO PRPH2
14 yemenite deaf-blind hypopigmentation syndrome 31.7 USH2A RPE65 RHO GUCY2D CFH CEP290
15 retinitis pigmentosa 31.7 USH2A RPGR RPE65 RLBP1 RHO PRPH2
16 macular degeneration, age-related, 1 31.6 USH2A RPGR RPE65 RLBP1 RHO PRPH2
17 macular retinal edema 31.3 RHO CRB1 CFH BEST1
18 cone-rod dystrophy 2 31.2 USH2A RPGR RPE65 RLBP1 RHO PRPH2
19 usher syndrome 31.1 USH2A RPGR RPE65 RLBP1 RHO PRPH2
20 eye disease 31.1 USH2A RPGR RPE65 RLBP1 RHO PRPH2
21 bardet-biedl syndrome 31.1 USH2A RPGR RPE65 RHO PRPH2 PRPF31
22 central serous chorioretinopathy 31.0 CFH ARMS2
23 usher syndrome type 2 31.0 USH2A RPGR RPE65 RHO PRPH2 PDE6B
24 congenital stationary night blindness 31.0 USH2A RPGR RPE65 RLBP1 RHO PRPH2
25 pattern dystrophy 30.9 RHO PRPH2 CRX
26 fundus dystrophy 30.9 USH2A RPGR RPE65 RLBP1 RHO PRPH2
27 stargardt disease 1 30.9 RHO PRPH2 CRX CRB1 BEST1 ABCA4
28 retinoschisis 1, x-linked, juvenile 30.9 USH2A RPGR RPE65 RHO NR2E3 GUCY2D
29 pathologic nystagmus 30.9 RPGR RPE65 RHO GUCY2D CRX CRB1
30 achromatopsia 30.9 USH2A RPGR RPE65 RHO PRPH2 PDE6B
31 choroideremia 30.8 USH2A RPGR RPE65 RHO PRPH2 GUCY2D
32 usher syndrome, type i 30.8 USH2A RPGR RPE65 RHO PDE6B CRX
33 scotoma 30.8 USH2A RPGR RPE65 RHO GUCY2D GUCA1A
34 leber congenital amaurosis 8 30.7 RPE65 GUCY2D CRX CRB1 AIPL1
35 leber congenital amaurosis 13 30.6 CEP290 AIPL1
36 leber congenital amaurosis 12 30.6 RPE65 GUCY2D GUCA1A AIPL1
37 occult macular dystrophy 30.6 RHO PRPH2 GUCY2D ABCA4
38 choroiditis 30.6 CFH ARMS2 ABCA4
39 pigmented paravenous chorioretinal atrophy 30.6 GUCY2D CRB1 AIPL1 ABCA4
40 leber congenital amaurosis 1 30.6 RPE65 RHO PRPH2 GUCY2D GUCA1A CRX
41 macular dystrophy, dominant cystoid 30.6 USH2A RPGR RPE65 RHO NR2E3 CRB1
42 leber congenital amaurosis 9 30.6 RPE65 GUCY2D CRX CRB1 CEP290 AIPL1
43 leber congenital amaurosis 3 30.6 RPE65 GUCY2D CRX CRB1 CEP290 AIPL1
44 leber congenital amaurosis 2 30.6 RPGR RPE65 RHO GUCY2D CRX CRB1
45 leber congenital amaurosis 7 30.6 GUCY2D CRX CRB1 AIPL1
46 leber congenital amaurosis 16 30.6 GUCY2D CRB1 AIPL1
47 doyne honeycomb retinal dystrophy 30.6 PRPH2 CFH BEST1 ARMS2 ABCA4
48 peripheral retinal degeneration 30.6 RLBP1 RHO PRPH2 CRB1 BEST1 ABCA4
49 retinitis pigmentosa 7 30.6 RPGR PRPH2 GUCA1A
50 leber congenital amaurosis 4 30.6 RPE65 GUCY2D CRX CRB1 CEP290 AIPL1

Graphical network of the top 20 diseases related to Retinal Disease:



Diseases related to Retinal Disease

Symptoms & Phenotypes for Retinal Disease

UMLS symptoms related to Retinal Disease:


eye manifestations

MGI Mouse Phenotypes related to Retinal Disease:

46
# Description MGI Source Accession Score Top Affiliating Genes
1 nervous system MP:0003631 10.09 ABCA4 AIPL1 CACNA1F CEP290 CFH CRB1
2 cardiovascular system MP:0005385 9.96 ABCA4 CACNA1F CEP290 CFH CRB1 CRX
3 pigmentation MP:0001186 9.77 ABCA4 BEST1 CEP290 CFH CRB1 CRX
4 vision/eye MP:0005391 9.6 ABCA4 AIPL1 BEST1 CACNA1F CEP290 CFH

Drugs & Therapeutics for Retinal Disease

Drugs for Retinal Disease (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 352)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Levoleucovorin Approved, Investigational Phase 4 68538-85-2 149436
2
Pioglitazone Approved, Investigational Phase 4 111025-46-8 4829
3
Methylcobalamin Approved, Investigational Phase 4 13422-55-4
4
Hydroxocobalamin Approved Phase 4 13422-51-0 11953898 15589840
5
Bevacizumab Approved, Investigational Phase 4 216974-75-3
6
Benserazide Approved, Investigational Phase 4 322-35-0
7
Levodopa Approved Phase 4 59-92-7 6047
8
Ephedrine Approved Phase 4 299-42-3 9294
9
Phenylephrine Approved Phase 4 59-42-7 6041
10
Pseudoephedrine Approved Phase 4 90-82-4 7028
11
Oxymetazoline Approved, Investigational Phase 4 1491-59-4 4636
12
Dipivefrin Approved Phase 4 52365-63-6 3105
13
Latanoprost Approved, Investigational Phase 4 130209-82-4 5282380 5311221
14
Nitrous oxide Approved, Vet_approved Phase 4 10024-97-2 948
15
Tropicamide Approved, Investigational Phase 4 1508-75-4 5593
16
Propofol Approved, Investigational, Vet_approved Phase 4 2078-54-8 4943
17
Ketamine Approved, Vet_approved Phase 4 6740-88-1 3821
18
Sevoflurane Approved, Vet_approved Phase 4 28523-86-6 5206
19
Dexamethasone Approved, Investigational, Vet_approved Phase 4 50-02-2 5743
20
Dexamethasone acetate Approved, Investigational, Vet_approved Phase 4 1177-87-3
21
Prednisolone Approved, Vet_approved Phase 4 50-24-8 5755
22
Methylprednisolone Approved, Vet_approved Phase 4 83-43-2 6741
23
Methylprednisolone hemisuccinate Approved Phase 4 2921-57-5
24
Prednisolone phosphate Approved, Vet_approved Phase 4 302-25-0
25
Prednisolone acetate Approved, Vet_approved Phase 4 52-21-1
26
Fluorouracil Approved Phase 4 51-21-8 3385
27
Fenofibrate Approved Phase 4 49562-28-9 3339
28
Lomustine Approved, Investigational Phase 4 13010-47-4 3950
29
tannic acid Approved Phase 4 1401-55-4
30
Benzocaine Approved, Investigational Phase 4 1994-09-7, 94-09-7 2337
31
Simvastatin Approved Phase 4 79902-63-9 54454
32
Ketorolac Approved Phase 4 74103-06-3, 66635-83-4 3826
33
Tesamorelin Approved, Investigational Phase 4 218949-48-5
34
Mannitol Approved, Investigational Phase 4 69-65-8 6251 453
35
Cyanocobalamin Approved, Nutraceutical Phase 4 68-19-9 44176380
36
Pyridoxine Approved, Investigational, Nutraceutical, Vet_approved Phase 4 65-23-6 1054
37
2,4-thiazolidinedione Investigational Phase 4 2295-31-0
38
Cobalamin Experimental Phase 4 13408-78-1 6857388
39
Prednisolone hemisuccinate Experimental Phase 4 2920-86-7
40 Hematinics Phase 4
41 Vitamin B 6 Phase 4
42 Vitamin B12 Phase 4
43 Vitamin B 12 Phase 4
44 (T,G)-A-L Phase 4
45
Glatiramer Acetate Phase 4 147245-92-9 3081884
46 Angiogenesis Inhibitors Phase 4
47 Neurotransmitter Agents Phase 4
48 Benserazide, levodopa drug combination Phase 4
49 Antiparkinson Agents Phase 4
50 Antineoplastic Agents, Immunological Phase 4

Interventional clinical trials:

(show top 50) (show all 646)
# Name Status NCT ID Phase Drugs
1 Pilot Study Investigating the Use of Intravitreal Ranibizumab in the Treatment of Vitreous Hemorrhage in Proliferative Diabetic Retinopathy Unknown status NCT01824043 Phase 4 intravitreal ranibizumab injections
2 A Pilot Study to Determine if Intravitreal Injections of Pegaptanib Sodium (Macugen) Given Every 12 Weeks for a Year After an Induction Phase of Three Injections Every 6 Weeks Will Reduce the Progression of Proliferative Diabetic Retinopathy in Patients Without Significant Vitreous Hemorrhage in Comparison to Treatment With Retinal Photocoagulation Alone and After an Induction Phase Unknown status NCT01486771 Phase 4 Macugen ® (pegaptanib sodium)
3 The Effects of Thiazolidinedione on the Diabetic Retinopathy and Nephropathy Unknown status NCT01175486 Phase 4 Actos (Pioglitazone);Acarbose
4 Effect of Folic Acid, Vitamin B6 and Vitamin B12 in Diabetic Retinopathy Unknown status NCT01921192 Phase 4 Folic Acid, vit B6 and B12;Placebo
5 Pattern Scan Laser System vs Regular Photocoagulation System: Changes in Macular Edema Post Treatment. Unknown status NCT00563628 Phase 4
6 Pattern Scan Laser System vs Regular Photocoagulation System: Changes in Electroretinograms and Contrast Sensitivity Post Treatment. Unknown status NCT00563043 Phase 4
7 CPAP Application at Delivery Room at Very Low Birth Weight Infants Unknown status NCT01024361 Phase 4
8 Effects of Glatiramer Acetate (Copaxone) in the Nerve Fiber Layer Thickness and Retinal Function in Diabetic Patients After Pan- Retinal Photocoagulation (PRP), a Double- Masked Randomized Clinical Trial. Unknown status NCT00677664 Phase 4 Glatiramer acetate (Copaxone);Mannitol
9 Panretinal Photocoagulation for Proliferative Diabetic Retinopathy in a Single Session Using Low Fluence Parameters Unknown status NCT01023698 Phase 4
10 Different Day Regimes of Preoperative CONbercept Administration on CytokinEs of Proliferative Diabetic Retinopathy Patients Undergoing Vitrectomy: a Prospective Randomized Controlled Clinical Trial (CONCEPT) Unknown status NCT03506750 Phase 4 IVC
11 Three Arm, Prospective, Single-blind, Randomized Study Comparing Ranibizumab Plus Green Diode Laser Versus Ranibizumab Plus Pattern Scan Laser (Pascal) Versus Ranibizumab (Monotherapy) for Proliferative Diabetic Retinopathy. Unknown status NCT02005432 Phase 4 Intravitreal Ranibizumabe;panfotocoagulation (PASCAL);panfotocoagulation (PRP) single shoot (ETDRS)
12 The Effect of Bevacizumab on Peripheral Retinal Changes as Imaged by Wide -Field Fluorescein Angiography in Diabetic Macular Edema Unknown status NCT02096874 Phase 4 Bevacizumab
13 Effect of Doxium on High Sensitivity CRP and Endothelin-1 Serum Levels in Patients With Diabetic Retinopathy Unknown status NCT01382498 Phase 4 Calcium dobesilate (Doxium);Placebo drug
14 A 12 Months, Prospective, Multicenter, Open-label, Single Arm Interventional Study Assessing the Safety and Tolerability of 0.5 mg Ranibizumab in Mono/Bilateral Wet AMD Patients in Eyes With (Best-Corrected Distance Visual Acuity) BCVA Below 2/10 and/or Second Affected Eye Completed NCT01986907 Phase 4 ranibizumab
15 Efficacy of Ranibizumab Therapy With Aflibercept in Patients With Diabetic Macular Edema Completed NCT02646670 Phase 4 Ranibizumab;Aflibercept;Ranibizumab and Aflibercept;Aflibercept and ranibizumab
16 Effect of Levodopa on Human Multifocal Electroretinogram Completed NCT00812760 Phase 4 levodopa
17 Evaluation of Diabetic Retinopathy Progression in Subjects With Type 2 Diabetes Mellitus Treated With Insulin Completed NCT00174824 Phase 4 Insulin glargine
18 Prospective, Single-center, Six-month Study of Intravitreal Ranibizumab for Macular Edema With Nonproliferative Diabetic Retinopathy: Effects on Microaneurysm Turnover and Non-perfused Retinal Area Completed NCT02834663 Phase 4 Lucentis
19 Effects of Fenofibrate on Endothelial Progenitor Cell Levels in Diabetic Patients With Retinopathy. A Randomized Controlled Trial. Completed NCT01927315 Phase 4 Fenofibrate 145 mg;Placebo
20 Prospective Randomized Controlled Study of Intravitreal Injection of 0.16 mg Bevacizumab One Day Before Surgery for Proliferative Diabetic Retinopathy Completed NCT01854593 Phase 4 Bevacizumab
21 A Multicenter, Randomized, Double-blind Non-inferiority Trial to Evaluate the Efficacy and Safety of Entelon® as Compared to Doxium Tab. And Placebo for the Treatment of Nonproliferative Diabetic Retinopathy Completed NCT03962296 Phase 4 Vitis vinifera extract;Calcium Dobesilate;Placebo
22 Different Conbercept Injection Methods in Treatment of Severe Proliferative Diabetic Retinopathy Completed NCT02816710 Phase 4 Conbercept
23 Vascular Endothelial Growth Factor Levels in Aqueous, Vitreous and Subretinal Fluid in Patients With Retinopathy of Prematurity Stage V. Completed NCT00500396 Phase 4
24 Ranibizumab Treatment of Diabetic Macular Oedema With Bimonthly Monitoring After a Phase of Initial Treatment. A UK, 18-month, Prospective, Open-label, Multicentre, Single-arm, Phase IIIb Study With 12-month Primary Endpoint, Assessing the Efficacy and Safety of Ranibizumab in Patients With Visual Impairment Due to Diabetic Macular Oedema. Completed NCT01257815 Phase 4 Ranibizumab
25 Comparison of the Vascular Endothelial Growth Factor Serum Concentrations After Intravitreal Use of Bevacizumab or Ranibizumab as a Treatment for Type 1 Retinopathy of Prematurity Completed NCT03148132 Phase 4 Bevacizumab Injection;Ranibizumab Ophthalmic
26 Topical Application of Latanoprost in Diabetic Retinopathy Completed NCT01225653 Phase 4 Latanoprost
27 Vascular Endothelial Growth Factor Levels in Aqueous, Vitreous and Subretinal Fluid in Patients With Retinopathy of Prematurity Stage IV and V Completed NCT00563121 Phase 4
28 Efficacy and Safety of Mydriatic Microdrops Compared With Standard Drops for Retinopathy of Prematurity (ROP) Screening: a Pilot Randomized Clinical Trial Completed NCT04623684 Phase 4 Microdrop administration [phenylephrine 1.67% + tropicamide 0.33% (drop volume: 6-7 μL)];Standard drop administration [phenylephrine 1.67% + tropicamide 0.33% (drop volume: 28-34 μL)]
29 Investigator Initiated Observational Study of Intravitreal Aflibercept Injection in Subjects With Diabetic Macular Edema Previously Treated With Ranibizumab or Bevacizumab Completed NCT02559180 Phase 4 aflibercept
30 Intravitreal Bevacizumab for Surgical Treatment of Severe Proliferative Diabetic Retinopathy Completed NCT01025934 Phase 4 Bevacizumab
31 Morphological and Functional Retinal Changes Following Retinal Photocoagulation Using a Semiautomated Patterned Scanning Laser System in Proliferative Retinopathy or Macular Edema Secondary to Diabetes Mellitus or Retinal Vein Occlusion Completed NCT00682240 Phase 4
32 DECREASING THE NEED FOR MECHANICAL VENTILATION AFTER RETINOPATHY OF PREMATURITY SURGERY: Sedation vs General Anesthesia Completed NCT01955135 Phase 4 Ketamine;Sevoflurane;propofol
33 Sucrose and Non Nutritive Suck as Analgesia for Babies Undergoing Retinopathy of Prematurity Screening; a Randomised Placebo Controlled Trial Completed NCT00921544 Phase 4
34 Pain Using Reduced Fluence Parameters in Photocoagulation for Diabetic Retinopathy. Completed NCT00802269 Phase 4
35 Intravitreal Bevacizumab for Proliferative Diabetic Retinopathy With New Dense Vitreous Hemorrhage After Full Panretinal Photocoagulation Completed NCT01724385 Phase 4 intravitreal injection of bevacizumab
36 Macular Perfusion Changes in Proliferative Diabetic Retinopathy Following Anti-VEGF Therapy Versus Targeted and Pan-retinal Photocoagulation Using Optical Coherence Tomography Angiography Recruiting NCT04674254 Phase 4 Bevacizumab Injection
37 A Randomised Placebo-controlled Trial of Fenofibrate to Prevent Progression of Non-proliferative Retinopathy in Diabetes Recruiting NCT03439345 Phase 4 Fenofibrate 145 mg;Placebo Oral Tablet
38 DEXTENZA VS. PREDNISOLONE ACETATE 1% in the Incidence of Pseudophakic Macular Edema in Patients With Diabetic Retinopathy Undergoing Cataract Surgery Recruiting NCT04362241 Phase 4 Prednisolone Acetate 1% Ophthalmic Suspension [PRED FORTE]
39 Increase in Capillary Plexus Density Level Following the Use of Ozurdex for the Treatment of DME (RMSM ICOD STUDY) Recruiting NCT04038125 Phase 4 Ozurdex Drug Implant Product
40 Effect of Continuous Positive Airway Pressure on the Progression of Vascular Retinal Disease in Patients With Sleep Apnea and Non-proliferative Diabetic Retinopathy. A Randomized Clinical Trial Active, not recruiting NCT02874313 Phase 4 Pharmacological treatment
41 A Phase IV Randomised Clinical Trial of Laser Therapy for Peripheral Retinal Ischaemia Combined With Intravitreal Aflibercept (Eylea®) Versus Intravitreal Aflibercept Monotherapy for Diabetic Macular Oedema Active, not recruiting NCT02432547 Phase 4 Aflibercept
42 Outpatient Performed Pterygium Surgery Study Not yet recruiting NCT03037736 Phase 4 5-Fluorouracil;Bevacizumab;Normal saline
43 Long-Term Efficacy and Safety of Intravitreal Aflibercept Injections for the Treatment of Diabetic Retinopathy for Subjects Who Completed the 2-Year PANORAMA Trial Not yet recruiting NCT04708145 Phase 4 Aflibercept Injection
44 The Evaluation of Retinal PhotoReceptors And Vasculature in Moderate and Severe Non-proliferative Diabetic Retinopathy Patients After Intravitreal Aflibercept on Using Adaptive Optics Imaging Study (PRAVA) Study Not yet recruiting NCT04702048 Phase 4 Aflibercept Injection;Sham injection
45 A 52-week, Two Arm, Randomized, Open-label, Multicenter Study Assessing the Efficacy and Safety of Two Different Brolucizumab 6 mg Dosing Regimens for Patients With Suboptimal Anatomically Controlled Neovascular Age-related Macular Degeneration Not yet recruiting NCT04679935 Phase 4
46 Prospective, Single-blind, Randomised, Controlled, Multi-centre Study to Evaluate the Benefit of Ranibizumab as an Adjunctive Therapy to Vitrectomy for Patients With Proliferative Diabetic Retinopathy Combined With Diabetic Macular Oedema Not yet recruiting NCT04464694 Phase 4 Ranibizumab
47 Efficacy of Calcium Dobesilate in Treating Chinese Patients With Mild to Moderate Non-proliferative Diabetic Retinopathy (CALM-DR): a Single-blind, Multicenter, Cluster-randomized, Controlled Trial Not yet recruiting NCT04283162 Phase 4 Calcium Dobesilate
48 Evaluation of Lipid Lowering Agents on Diabetic Retinopathy and Cardiovascular Risk of Diabetic Patients Not yet recruiting NCT04140201 Phase 4 Simvastatin 40mg;Fenofibrate 200mg;Omega 3 fatty acid
49 A Prospective, Randomized, Placebo-controlled, Double-blind Clinical Trial to Evaluate Whether EGRIFTA® (Tesamorelin for Injection), 2 mg Once Daily SC, Increases the Risk of Development or Progression of Diabetic Retinopathy When Administered to HIV-infected Subjects With Abdominal Lipohypertrophy and Concomitant Diabetes Terminated NCT01591902 Phase 4 Tesamorelin;Placebo-Control
50 Topical Application of ACULAR a Randomized, Vehicle Controlled Clinical Trial: Efficiency in Inhibiting Proliferative Retinopathy of Prematurity Terminated NCT00634972 Phase 4 ACULAR;REFRESH TEARS;placebo

Search NIH Clinical Center for Retinal Disease

Cochrane evidence based reviews: retinal diseases

Genetic Tests for Retinal Disease

Anatomical Context for Retinal Disease

The Foundational Model of Anatomy Ontology organs/tissues related to Retinal Disease:

19
Retina

MalaCards organs/tissues related to Retinal Disease:

40
Retina, Eye, Endothelial, Bone Marrow, Bone, Skin, Cortex

Publications for Retinal Disease

Articles related to Retinal Disease:

(show top 50) (show all 5550)
# Title Authors PMID Year
1
Macular diseases in Ibadan, Nigeria. 42
33723107 2021
2
Profile of patients receiving intravitreal anti-vascular endothelial growth factor injections during COVID-19-related lockdown. 42
33595512 2021
3
Short term visual and structural outcomes of anti-vascular endothelial growth factor (anti-VEGF) treatment delay during the first COVID-19 wave: A pilot study. 42
33596257 2021
4
Luteolin delays photoreceptor degeneration in a mouse model of retinitis pigmentosa. 61
33642401 2021
5
The neuroprotective role of Wnt signaling in the retina. 61
33433466 2021
6
OFF bipolar cell density varies by subtype, eccentricity, and along the dorsal ventral axis in the mouse retina. 61
33135176 2021
7
The inducible nitric oxide synthase-inhibitor 1400W as a potential treatment for retinal diseases. 61
33269785 2021
8
Drug-related adverse effects of antivascular endothelial growth factor agents. 61
33770015 2021
9
Mutant three-repeat tau expression initiates retinal ganglion cell death through Caspase-2. 61
33516874 2021
10
The therapeutic use of quercetin in ophthalmology: recent applications. 61
33561647 2021
11
Müller Glia-Mediated Retinal Regeneration. 61
33417229 2021
12
Investigational neuroprotective compounds in clinical trials for retinal disease. 61
33641585 2021
13
Quantification of BNN27, a novel neuroprotective 17-spiroepoxy dehydroepiandrosterone derivative in the blood and retina of rodents, after single intraperitoneal administration. 61
33638308 2021
14
Updating the Staging System for Diabetic Retinal Disease. 61
33218709 2021
15
A New Era in Reducing Treatment Burden in Retinal Disease. 61
33787534 2021
16
Methodological Challenges in the Economic Evaluation of a Gene Therapy for RPE65-Mediated Inherited Retinal Disease: The Value of Vision. 61
33604870 2021
17
Co-delivery of glial cell-derived neurotrophic factor (GDNF) and tauroursodeoxycholic acid (TUDCA) from PLGA microspheres: potential combination therapy for retinal diseases. 61
33641047 2021
18
Involvement of TRPM2 Channel on Hypoxia-Induced Oxidative Injury, Inflammation, and Cell Death in Retinal Pigment Epithelial Cells: Modulator Action of Selenium Nanoparticles. 61
33389617 2021
19
Mammalian Retinal Cell Quantification. 61
33380270 2021
20
Taurine and oxidative stress in retinal health and disease. 61
33621439 2021
21
Ferrostatin-1 attenuates ferroptosis and protects the retina against light-induced retinal degeneration. 61
33631670 2021
22
Transcriptome Landscape of Epithelial to Mesenchymal Transition of Human Stem Cell-Derived RPE. 61
33792620 2021
23
Imaging the pediatric retina: An overview. 61
33727440 2021
24
Ubiquitous Chromatin Modifiers in Congenital Retinal Diseases: Implications for Disease Modeling and Regenerative Medicine. 61
33573910 2021
25
A detailed and comparative work for retinal vessel segmentation based on the most effective heuristic approaches. 61
33768764 2021
26
MULTIPLE INTRAVITREAL INJECTIONS DO NOT CAUSE ANTERIOR SCLERAL THINNING: An Ultrasound Biomicroscopy Study. 61
32804831 2021
27
PARTICULATE MATTER FROM SYRINGES USED FOR INTRAVITREAL INJECTIONS. 61
32956210 2021
28
Cell Surface Profiling of Retinal Müller Glial Cells Reveals Association to Immune Pathways after LPS Stimulation. 61
33806940 2021
29
For which diseases do broader value elements matter most? An evaluation across 20 ICER evidence reports. 61
33779245 2021
30
Generation of two induced pluripotent stem cell lines from a patient with recessive inherited retinal disease caused by compound heterozygous mutations in SNRNP200. 61
33429167 2021
31
Single-cell RNA sequencing: A new opportunity for retinal research. 61
33754496 2021
32
Correlation of ocular rigidity with intraocular pressure spike after intravitreal injection of bevacizumab in exudative retinal disease. 61
32345604 2021
33
The endocannabinoid 2-arachidonoylglycerol and dual ABHD6/MAGL enzyme inhibitors display neuroprotective and anti-inflammatory actions in the in vivo retinal model of AMPA excitotoxicity. 61
33450278 2021
34
Integrative Biology of Diabetic Retinal Disease: Lessons from Diabetic Kidney Disease. 61
33803590 2021
35
OctNET: A Lightweight CNN for Retinal Disease Classification from Optical Coherence Tomography Images. 61
33339630 2021
36
Safety and Tolerability of Topical Ophthalmic Triamcinolone Acetonide-Loaded Liposomes Formulation and Evaluation of Its Biologic Activity in Patients with Diabetic Macular Edema. 61
33801366 2021
37
Toxicity Screens in Human Retinal Organoids for Pharmaceutical Discovery. 61
33749682 2021
38
Serine biosynthesis defect due to haploinsufficiency of PHGDH causes retinal disease. 61
33758422 2021
39
Identification of genetic factors influencing metabolic dysregulation and retinal support for MacTel, a retinal disorder. 61
33654266 2021
40
Sex differences in risk factors for cognitive decline and dementia, including death as a competing risk, in individuals with diabetes: Results from the ADVANCE trial. 61
33783955 2021
41
Predicting the safety zone for steroid-induced ocular hypertension induced by intravitreal dexamethasone implantation. 61
33737305 2021
42
Inflammatory Complications of Intravitreal Anti-VEGF Injections. 61
33801185 2021
43
Drug-related adverse effects of antivascular endothelial growth factor agents. 61
33769327 2021
44
Remote screening of retinal and optic disc diseases using handheld nonmydriatic cameras in programmed routine occupational health checkups onsite at work centers. 61
32728935 2021
45
Cytotoxicity of β-Cyclodextrins in Retinal Explants for Intravitreal Drug Formulations. 61
33803405 2021
46
Anti-VEGF intravitreal injections in the era of COVID-19: responding to different levels of epidemic pressure. 61
33528647 2021
47
Telegenetics for inherited retinal diseases in the COVID-19 environment. 61
33781332 2021
48
Intravitreal injections during COVID-19 outbreak: Protective measures, total duration of care and perceived quality of care in a tertiary retina center. 61
33752454 2021
49
COVID-19 Launches Retinal Telemedicine into the Next Frontier. 61
33651652 2021
50
First 3D-Structural Data of Full-Length Guanylyl Cyclase 1 in Rod-Outer-Segment Preparations of Bovine Retina by Cross-Linking/Mass Spectrometry. 61
33744315 2021

Variations for Retinal Disease

Expression for Retinal Disease

Search GEO for disease gene expression data for Retinal Disease.

Pathways for Retinal Disease

GO Terms for Retinal Disease

Cellular components related to Retinal Disease according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 cell projection GO:0042995 9.92 USH2A RPGR RHO PRPH2 GUCY2D GUCA1A
2 photoreceptor disc membrane GO:0097381 9.55 RHO PDE6B GUCY2D GUCA1A ABCA4
3 photoreceptor inner segment GO:0001917 9.5 USH2A RHO PRPH2 GUCA1A CRB1 ARMS2
4 photoreceptor outer segment membrane GO:0042622 9.43 RHO PDE6B GUCY2D
5 photoreceptor outer segment GO:0001750 9.28 RPGR RHO PRPH2 PDE6B GUCY2D GUCA1A

Biological processes related to Retinal Disease according to GeneCards Suite gene sharing:

(show all 18)
# Name GO ID Score Top Affiliating Genes
1 response to stimulus GO:0050896 9.83 USH2A RPGR RPE65 RLBP1 RHO PRPH2
2 retinoid metabolic process GO:0001523 9.73 RPE65 RLBP1 RHO ABCA4
3 retina development in camera-type eye GO:0060041 9.73 RPE65 RHO PRPH2 PDE6B NR2E3 CRB1
4 regulation of rhodopsin mediated signaling pathway GO:0022400 9.72 RHO PDE6B GUCY2D GUCA1A AIPL1
5 photoreceptor cell maintenance GO:0045494 9.71 USH2A RHO CRB1 ABCA4
6 retina homeostasis GO:0001895 9.69 RPE65 ARMS2 AIPL1
7 phototransduction, visible light GO:0007603 9.67 RHO PDE6B AIPL1 ABCA4
8 phototransduction GO:0007602 9.65 RHO NR2E3 GUCA1A
9 eye photoreceptor cell development GO:0042462 9.63 NR2E3 CRB1 CEP290
10 cellular response to light stimulus GO:0071482 9.58 RHO CRB1
11 sensory perception of light stimulus GO:0050953 9.57 USH2A RHO
12 photoreceptor cell outer segment organization GO:0035845 9.56 PRPH2 CRB1
13 retina morphogenesis in camera-type eye GO:0060042 9.55 RPE65 CRB1
14 detection of light stimulus involved in visual perception GO:0050908 9.55 RPE65 PRPH2 CRB1 CACNA1F BEST1
15 rhodopsin mediated signaling pathway GO:0016056 9.54 RHO PDE6B
16 visual perception GO:0007601 9.53 USH2A RPGR RPE65 RLBP1 RHO PRPH2
17 vitamin A metabolic process GO:0006776 9.52 RPE65 RLBP1
18 detection of light stimulus GO:0009583 9.49 RHO PDE6B

Molecular functions related to Retinal Disease according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 11-cis retinal binding GO:0005502 8.62 RLBP1 RHO

Sources for Retinal Disease

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 EFO
18 ExPASy
19 FMA
20 GARD
28 GO
29 GTR
30 HMDB
31 HPO
32 ICD10
33 ICD10 via Orphanet
34 ICD9CM
35 IUPHAR
36 KEGG
37 LifeMap
39 LOVD
41 MedGen
44 MeSH
45 MESH via Orphanet
46 MGI
49 NCI
50 NCIt
51 NDF-RT
53 NINDS
54 Novoseek
56 OMIM via Orphanet
57 OMIM® (Updated 05-Apr-2021)
61 PubMed
63 QIAGEN
68 SNOMED-CT via HPO
69 Tocris
70 UMLS
71 UMLS via Orphanet
Content
Loading form....